Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

Tremfya is a fully human antibody created to neutralise inflammation by blocking IL-23, a cytokine that plays a part in autoimmune and inflammatory diseases. It is currently approved in the US for ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery ...